20221027104337.jpg&width=400&height=400)
Ancient Chinese traditional medicine significantly reduces the side effects of rectal cancer treatments that, in some patients, can be so toxic that treatment must be paused, or stopped, which diminishes its effectiveness.
The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial.
In addition to earning the sixth spot nationally in Psychiatry, Yale New Haven Hospital ranked well in Obstetrics and Gynecology (#19), Otolaryngology (Ear Nose and Throat) (#27), Geriatrics (#28), Diabetes and Endocrinology (#29) Pulmonology and Lung Surgery (#31), Urology (#31), Heart and Heart Surgery (#43) Cancer (#45), Neurology and Neurosurgery (#48) and Gastroenterology and GI Surgery (#50).
Sneaking by cancer’s defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at the Yale School of Medicine (YSM).
Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers.
New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.
Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy.
Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study.
“The COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab,” explained Dr. Herbst, who will present the findings at ASCO.
The study, which joins a growing body of research on end-of-life cancer treatment, published May 16 in JAMA Oncology.
Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill.
Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) have again received an internationally recognized accreditation for cellular therapy and stem cell transplantation from the Foundation for the Accreditation of Cellular Therapy (FACT), giving patients life-saving cancer treatment options in Connecticut.
A study led by Yale scientists, published April 25 in the journal Science Immunology, investigated the potential causes associated with T cell exclusion using a genome-wide screen of more than 1,000 human proteins.
Connecticut Magazine released its “Top Doctors” issue today, listing some of the state’s best physicians, who provide exceptional care for patients. This year’s list includes 109 Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) physicians, a 35% increase in “Top Doctors” for SCH and YCC from last year.
Cervical cancer, often caused by persistent human papillomavirus (HPV) infections, remains a public health challenge worldwide despite falling diagnoses related to the success of the HPV vaccine[GR1] in young adult women.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
